Company Gets $1.6 Billion From U.S. Government for COVID-19 Vaccine

Novavax has never brought a product to market before

syringe

TUESDAY, July 7, 2020 (HealthDay News) -- Vaccine maker Novavax will receive $1.6 billion from the U.S. government to provide 100 million doses of a COVID-19 vaccine by early 2021, the Maryland-based company said Monday.

This is the largest deal announced by the Trump administration to date as part of its attempts to provide COVID-19 vaccines and treatments to Americans as soon as possible, The New York Times reported.

The $1.6 billion is coming from a "collaboration" between the Health and Human Services Department and the Defense Department, according to a Novavax spokeswoman. Novavax has never brought a product to market, The Times reported.

In May, the Trump administration said it would give up to $1.2 billion to British pharmaceutical company AstraZeneca, which has said it could have a vaccine available by October. Federal funding has also been given to four other companies -- Moderna Therapeutics, Johnson & Johnson, Merck, and Sanofi -- for their experimental COVID-19 vaccines, The Times reported.

The New York Times Article

Physician’s Briefing Staff

Physician’s Briefing Staff

Published on July 07, 2020

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ